Founded by Professor Mark Waller, Pending AI has developed a comprehensive discovery platform enabled by artificial intelligence and quantum mechanics, ushering in a new paradigm of medicinal innovation where higher-quality small molecule drugs can be developed in a fraction of the time and cost. With operational presences across both Cambridge, Massachusetts, United States and Eveleigh, New South Wales, Australia, Pending AI is actively seeking research-and-development partnerships with pharmaceutical companies, as well as to ascertain interest from investors in the company's upcoming investment round.